| Effect of cytomegalovirus reactivation with or without acute graft-versus-host disease on the risk of nonrelapse mortality Y Akahoshi, SI Kimura, Y Inamoto, S Seo, H Muranushi, H Shimizu, ... Clinical Infectious Diseases 73 (3), e620-e628, 2021 | 22 | 2021 |
| GVHD-free, relapse-free survival provides novel clues for optimizing allogeneic-HSCT for adult T-cell leukemia/lymphoma H Muranushi, T Shindo, M Hishizawa, M Tokunaga, A Wake, N Nakano, ... Bone Marrow Transplantation 56 (1), 155-166, 2021 | 12 | 2021 |
| Drug monitoring for mycophenolic acid in graft‐vs‐host disease prophylaxis in cord blood transplantation H Muranushi, J Kanda, Y Arai, T Shindo, M Hishizawa, T Yamamoto, ... British Journal of Clinical Pharmacology 86 (12), 2464-2472, 2020 | 10 | 2020 |
| Hairy cell leukemia with systemic lymphadenopathy: detection of BRAF mutations in both lymph node and peripheral blood specimens K Okada, A Kunitomi, K Sakai, H Muranushi, Y Okamoto, T Tsukamoto, ... Internal Medicine 54 (11), 1397-1402, 2015 | 5 | 2015 |
| Dual inhibition of the MEK/ERK and PI3K/AKT pathways prevents pulmonary GVHD suppressing perivenulitis and bronchiolitis H Muranushi, T Shindo, TF Chen-Yoshikawa, A Yoshizawa, H Thi Ngo, ... Blood Advances 7 (1), 106-121, 2023 | 3 | 2023 |
| Pharmacological MEK inhibition promotes polyclonal T-cell reconstitution and suppresses xenogeneic GVHD H Itamura, T Shindo, H Muranushi, K Kitaura, S Okada, T Shin, R Suzuki, ... Cellular Immunology 367, 104410, 2021 | 3 | 2021 |
| Pre-treatment WT1 mRNA expression level in peripheral blood predicts response and overall survival of myelodysplastic syndrome patients in the azacitidine era T Jo, K Sakai, H Muranushi, Y Okamoto, T Tsukamoto, H Sugiura, ... Blood 122 (21), 1528, 2013 | 2 | 2013 |
| Myeloid blast crisis in chronic myeloid leukemia with a unique deletion near the BCR/ABL breakpoint A Kunitomi, S Kimura, Y Okamoto, K Sakai, H Muranushi, T Tsukamoto, ... International Cancer Conference Journal 4, 26-28, 2015 | 1 | 2015 |
| Absolute lymphocyte count as an independent prognostic factor of IPI and NCCN-IPI in DLBCL patients K Okada, S Ochi, T Nagayama, S Nabe, K Sakai, H Muranushi, ... Blood, The Journal of the American Society of Hematology 124 (21), 1636-1636, 2014 | 1 | 2014 |
| Venetoclax and azacitidine therapy in acute myeloid leukemia patients with severe renal impairment R Naka, T Kondo, M Nishikubo, H Muranushi, Y Ueda, T Oka, F Wada, ... American journal of hematology 98 (9), E251-E254, 2023 | | 2023 |
| PB1862: VENETOCLAX AND AZACITIDINE THERAPY IN ACUTE MYELOID LEUKEMIA PATIENTS WITH SEVERE RENAL IMPAIRMENT R Naka, T Kondo, M Nishikubo, H Muranushi, Y Ueda, T Oka, F Wada, ... HemaSphere 7 (S3), e8463360, 2023 | | 2023 |
| Bortezomib-cyclophosphamide-dexamethasone induction/consolidation and bortezomib maintenance for transplant-eligible newly diagnosed multiple myeloma: phase 2 multicenter trial H Muranushi, J Kanda, M Kobayashi, T Maeda, T Kitano, M Tsuji, Y Ueda, ... Hematology 27 (1), 239-248, 2022 | | 2022 |
| Dual Inhibition of the MEK/ERK and PI3K/AKT Pathways Prevents Pulmonary Graft-Versus-Host Disease through Suppression of Arteriovenous Inflammation and Bronchiolitis H Muranushi, T Shindo, HT Ngo, F Gochi, A Yoshizawa, ... Blood 138, 3807, 2021 | | 2021 |
| Correction: GVHD-free, relapse-free survival provides novel clues for optimizing allogeneic-HSCT for adult T-cell leukemia/lymphoma H Muranushi, T Shindo, M Hishizawa, M Tokunaga, A Wake, N Nakano, ... Bone Marrow Transplantation 56 (1), 298, 2021 | | 2021 |
| Effect of Cytomegalovirus Reactivation with or Without Acute GVHD on the Risk of Nonrelapse Mortality Y Akahoshi, S Kimura, Y Inamoto, S Seo, H Muranushi, H Shimizu, ... | | 2020 |
| The MEK Inhibitor Trametinib Enhances Diverse T Cell Reconstitution with Suppressing Xenogeneic Graft-Versus-Host-Disease H Itamura, H Muranushi, T Shindo, K Kitaura, S Okada, T Shin, R Suzuki, ... Blood 134, 1929, 2019 | | 2019 |
| Graft-Versus-Host Disease-Free, Relapse-Free Survival in Allogeneic Stem Cell Transplantation for Adult T-Cell Leukemia/Lymphoma Provides a Novel Donor Selection Paradigm H Muranushi, T Shindo, M Hishizawa, M Tokunaga, A Wake, N Nakano, ... Blood 134, 2008, 2019 | | 2019 |
| Significance of drug monitoring for mycophenolic acid in GVHD prophylaxis in cord blood transplantation H Muranushi, J Kanda, T Shindo, M Hishizawa, T Kondo, K Yamashita, ... BONE MARROW TRANSPLANTATION 53, 451-451, 2018 | | 2018 |
| Pegfilgrastim for patients with malignant lymphoma in our hospital H Muranushi, A Ueda, R Takaya, S Ochi, T Nagayama, K Okada, A Sato, ... Annals of Oncology 27, vii97, 2016 | | 2016 |
| Peripheral Eosinophilia May Prevent Progression to Severe Acute GVHD after Allogeneic Hematopoietic Stem Cell Transplantation K Sakai, A Ueda, R Takaya, S Ochi, S Nabe, T Nagayama, H Muranushi, ... Biology of Blood and Marrow Transplantation 22 (3), S354-S355, 2016 | | 2016 |
